NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will host a satellite symposium at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego to spotlight its atrioventricular interval modulation (AVIM) therapy. The event, scheduled for April 25, will discuss the therapy’s potential to address hypertension in patients at increased cardiovascular risk.
The symposium follows the U.S. Food and Drug Administration’s recent granting of Breakthrough Device Designation (BDD) for AVIM therapy. The designation applies to an implantable system designed to reduce blood pressure using conduction system pacing in patients with uncontrolled hypertension who have high 10-year cardiovascular risk. Orchestra BioMed estimates that over 7.7 million patients in the U.S. could potentially benefit from this therapy.
Dr. Vivek Reddy, a leading electrophysiologist and chair of the symposium, emphasized its importance, saying, “The FDA’s recent grant of Breakthrough Device Designation to AVIM therapy… underscores the significant unmet need in higher risk patients as well as the strength of the clinical data generated to date.”
The symposium will feature presentations from experts on topics including the unmet needs in hypertension management, clinical results from MODERATO studies, and the design of the BACKBEAT global pivotal study. BACKBEAT, conducted in collaboration with Medtronic, evaluates AVIM therapy’s effectiveness in treating hypertension in patients with dual-chamber pacemakers.
With this initiative, Orchestra BioMed aims to reinforce the growing clinical evidence supporting AVIM therapy and its potential to reshape hypertension treatment for at-risk populations.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.